Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites-Reference-Cited by-同舟云学术

Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites

Published:2016-06-23 Issue:5 Volume:34 Page:636-642
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Takahara Naminatsu,Isayama Hiroyuki,Nakai Yousuke,Ishigami Hironori,Satoi Sohei,Mizuno Suguru,Kogure Hirofumi,Matsubara Saburo,Yamamoto Natsuyo,Yamaguchi Hironori,Tada Minoru,Kitayama Joji,Watanabe Toshiaki,Koike Kazuhiko

Funder

The Tokyo University Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-016-0369-0.pdf

Reference37 articles.

1. Takahara N, Isayama H, Nakai Y, et al. (2015) Pancreatic cancer with malignant ascites: clinical features and outcomes. Pancreas 44:380–385

2. Morizane C, Okusaka T, Morita S, et al. (2011) Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas 40:415–421

3. Thomassen I, Lemmens VE, Nienhuijs SW, et al. (2013) Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas 42:72–75

4. Von Hoff DD, Ervin T, Arena FP, et al. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703

5. Shukuya T, Yasui H, Boku N, et al. (2010) Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. Jpn J Clin Oncol 40:1135–1138

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Double‐Layered Metal‐Organic‐Frameworks‐Based Microswimmers for Adaptive Dual‐Drug Anti‐Cancer Therapy Using Artemisinin‐Based Compounds;Advanced Intelligent Systems;2024-06-20

2. Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites;Pancreatology;2024-06

3. Progress in the treatment of malignant ascites;Critical Reviews in Oncology/Hematology;2024-02

4. The complex role of IL-10 in malignant ascites: a review;Cancer Immunology, Immunotherapy;2024-01-27

5. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review;Cancer Treatment Reviews;2023-02